Patent ID: 7605179

Claim:
A method of treatment of a neurodegenerative disease or clinical dementia, either being associated with tau protein aggregation, which method comprises administering to a subject a therapeutically effective amount of a compound, wherein the compound is selected from a compound of formula II: wherein R 1A is —OMe, —OC(═O)Me, —COOH, —COOMe, —SO 3 H, —SO 3 M, or —SO 3 Me; R 2A is —H, unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; R 3 , R 4 , R 5 , and R 6 are independently —H, —OH, C 1-7 alkyl, C 1-7 alkoxy or acyloxy; and, M denotes a cation or cations of charge or cumulative charge to counter the charge on the —SO 3 — group; or a compound of formula III: or a compound of formula IV: wherein for formula III or IV: either (A) R 1A is unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; and R 2A is —H, unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; or (B) R 1A is —H, unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; and R 2A is unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; R 1B , if present, is —H, unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; R 2B , if present, is —H, unsubstituted C 1-7 alkyl, C 1-7 haloalkyl, C 1-7 hydroxyalkyl, C 1-7 aminoalkyl, C 1-7 carboxyalkyl, —OH, C 1-7 alkoxy, acyloxy, —COOH, ester, —SO 3 H, —SO 3 M, sulfonate, C 1-7 alkylsulfonate, or a short chain alkyl group; R 3 , R 4 , R 5 , and R 6 is independently —H, —OH, C 1-7 alkyl, C 1-7 alkoxy, or acyloxy; and, R 7 and R 8 is independently —H, C 1-7 alkyl, acyl, —SO 3 H, —SO 3 M, or sulfonate; M denotes a cation or cations of charge or cumulative charge to counter the charge on the —SO 3 group; and a pharmaceutically acceptable salt thereof, or a therapeutic composition comprising the same, such as to inhibit the aggregation of the protein associated with said disease or dementia.